🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchSURMOUNT-MMO: tirzepatide for morbid obesity — trial update Page 3

SURMOUNT-MMO: tirzepatide for morbid obesity — trial update

SurmountFan_IN Thu, May 28, 2026 at 7:56 PM 11 replies 436 viewsPage 3 of 3
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
May 31, 2026 at 6:51 PM#11
Dr.SurgeonPGH said:
The gap between trial results and real-world results is consistent and it is not fraud.

Agreed, and subgroup analyses deserve particular suspicion. With enough subgroups something is significant by chance, and pre-registered subgroups are a different animal from ones found afterwards.

Ask again with the specifics and you will get a better answer than this one.

20 20kim_atl_prep, sarah_TO, wendy_avl and 17 others
Reply Quote Save Share Report
MounjBrad
Member
278
890
Oct 2024
Kentucky
Jun 2, 2026 at 2:45 PM#12
tony_orlando said:
Agreed on the mechanism, with the caveat that the head-to-head used semaglutide 1mg, not 2.4mg.

This answered a question I did not know how to ask. Adding it to my notes with a link back to this thread.

19 19ben_calgary, patPC_UT, Dr.DermMIA and 16 others
Reply Quote Save Share Report
mia_MS2
New Member
8
23
Jun 2026
Ann Arbor, MI
Jun 4, 2026 at 10:40 AM#13
Dr.SurgeonPGH said:
The gap between trial results and real-world results is consistent and it is not fraud.

I read this differently from Dr.SurgeonPGH, on substance rather than tone. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

18 18dave_SLC, FDA_TrackerJim, ricardo_MIA and 15 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Jun 6, 2026 at 6:36 AM#14

One concrete data point for the thread. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.

Happy to go further on any of that.

17 17amsterdam_pete, LondonLisa, mike_nyc and 14 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 8, 2026 at 2:33 AM#15

Moderator note: the sourcing question belongs in the vendor section and has been split out. Report rather than reply if it drifts again.

Last edited: Jun 8, 2026 at 4:33 AM
16 16PurityPaulOR, MaxMetOK, MounjBrad and 13 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register